



PHARMACY COVERAGE GUIDELINES
SECTION: DRUGS

ORIGINAL EFFECTIVE DATE: 4/1/19
LAST REVIEW DATE: 2/21/19
LAST CRITERIA REVISION DATE:
ARCHIVE DATE:

RELISTOR® (methylnaltrexone bromide) oral tablet and subcutaneous injection

Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy Coverage Guideline must be read in its entirety to determine coverage eligibility, if any.

This Pharmacy Coverage Guideline provides information related to coverage determinations only and does not imply that a service or treatment is clinically appropriate or inappropriate. The provider and the member are responsible for all decisions regarding the appropriateness of care. Providers should provide BCBSAZ complete medical rationale when requesting any exceptions to these guidelines.

The section identified as "Description" defines or describes a service, procedure, medical device or drug and is in no way intended as a statement of medical necessity and/or coverage.

The section identified as "Criteria" defines criteria to determine whether a service, procedure, medical device or drug is considered medically necessary or experimental or investigational.

State or federal mandates, e.g., FEP program, may dictate that any drug, device or biological product approved by the U.S. Food and Drug Administration (FDA) may not be considered experimental or investigational and thus the drug, device or biological product may be assessed only on the basis of medical necessity.

Pharmacy Coverage Guidelines are subject to change as new information becomes available.

For purposes of this Pharmacy Coverage Guideline, the terms "experimental" and "investigational" are considered to be interchangeable.

BLUE CROSS®, BLUE SHIELD® and the Cross and Shield Symbols are registered service marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. All other trademarks and service marks contained in this guideline are the property of their respective owners, which are not affiliated with BCBSAZ.

This Pharmacy Coverage Guideline does not apply to FEP or other states' Blues Plans.

Information about medications that require precertification is available at www.azblue.com/pharmacy.

Some large (100+) benefit plan groups may customize certain benefits, including adding or deleting precertification requirements.

All applicable benefit plan provisions apply, e.g., waiting periods, limitations, exclusions, waivers and benefit maximums.

Precertification for medication(s) or product(s) indicated in this guideline requires completion of the request form in its entirety with the chart notes as documentation. All requested data must be provided. Once completed the form must be signed by the prescribing provider and faxed back to BCBSAZ Pharmacy Management at (602) 864-3126 or emailed to Pharmacyprecert@azblue.com. **Incomplete forms or forms without the chart notes will be returned.**

RELISTOR® (methylnaltrexone bromide) oral tablet and subcutaneous injection (cont.)

Criteria:

- **Criteria for initial therapy:** Relistor (methylnaltrexone bromide) is considered *medically necessary* and will be approved when **ALL** of the following criteria are met:
1. Prescriber is a physician specializing in or is in consultation with a Gastroenterologist or Oncologist
 2. Individual is 18 years of age or older
 3. A confirmed diagnosis of opioid-induced constipation (OIC) in **ONE** of the following:
 - Chronic non-cancer pain (including individuals with chronic pain related to prior cancer or its treatment) **AND** does not require frequent (e.g., weekly) opioid dosage escalation **AND** medical record documentation of a trial and failure of opioid dose reduction of at least $\geq 15\%$
 - Receiving palliative care for an advanced illness or pain caused by active cancer **AND** requires opioid dosage escalation
 4. Individual has been taking opiate medication for at least 4 weeks **AND** needs to continue opiate medication
 5. Failure of, contraindication to, or intolerance to **at least 1** medication from each of the following classes:
 - Oral senna with a stool softener used on schedule (not on an as needed basis) e.g. docusate sodium/Senna, Dok Plus, Peri-Colace, Senna-S, Senokot-S
 - Oral osmotic agent or saline agent used either routinely or on an as needed basis, e.g., Lactulose, Polyethylene glycol, Sorbitol
 - Oral or rectal stimulant used on an as needed basis e.g., Bisacodyl
 - Oral prokinetic agent used routinely (not on an as needed basis) e.g., Metoclopramide
 6. **Additional criteria for injection:** Failure of, contraindication to, or intolerance to the oral form of Relistor
 7. There are **NO** contraindications:
 - Known or suspected mechanical GI obstruction
 - Patients at increased risk of recurrent obstruction, due to the potential for gastrointestinal perforation

Initial Approval Duration:

- Opioid-induced constipation (OIC) chronic non-cancer pain: 6 months
- OIC palliative care for advanced illness: 4 months

- **Criteria for continuation of coverage (renewal request):** Relistor (methylnaltrexone bromide) is considered *medically necessary* and will be approved when **ALL** of the following criteria are met:

RELISTOR® (methylnaltrexone bromide) oral tablet and subcutaneous injection (cont.)

1. Individual continues to be seen by a physician specializing in or is in consultation with an Gastroenterologist or Oncologist
2. Individual's condition responded while on therapy
 - Response is defined as:
 - Achieved and maintains **ALL** of the following
 - Type 3 or 4 Bristol Stool Form
 - Three or more spontaneous bowel movements (SBMs)/week
 - SBM is defined as a bowel movements that occur without laxative use
3. Individual has been adherent with the medication **and** continues to require same opioid regimen (same drug, same dose, and same frequency) for pain control
4. Individual has not developed any contraindications or other significant level 4 adverse drug effects that may exclude continued use
 - Contraindications as listed in the criteria for initial therapy section
 - Significant adverse effect such as:
 - Gastrointestinal perforation
 - Severe, persistent, or worsening abdominal pain
 - Severe or persistent diarrhea
5. There are no significant interacting drugs

Renewal duration:

- Opioid-induced constipation (OIC) chronic non-cancer pain: 6 months
- OIC palliative care for advanced illness: 6 months

➤ Relistor (methylnaltrexone bromide) **oral or injection** for all other indications not previously listed or if above criteria not met is considered **experimental or investigational** based upon:

1. Lack of final approval from the Food and Drug Administration, and
2. Insufficient scientific evidence to permit conclusions concerning the effect on health outcomes, and
3. Insufficient evidence to support improvement of the net health outcome, and
4. Insufficient evidence to support improvement of the net health outcome as much as, or more than, established alternatives, and
5. Insufficient evidence to support improvement outside the investigational setting.

These indications include, *but are not limited to:*

- Treatment with dosing or frequency outside the FDA-approved dosing and frequency

RELISTOR® (methylnaltrexone bromide) oral tablet and subcutaneous injection (cont.)

Description:

Relistor (methylnaltrexone) **injection** is indicated for:

- Treatment of opioid-induced constipation (OIC) in adults with chronic non-cancer pain
- Treatment of OIC in adults with advanced illness who are receiving palliative care and response to laxative therapy has not been sufficient

Relistor (methylnaltrexone) oral **tablet** is indicated for the treatment of OIC in adult patients with chronic non-cancer pain.

Methylnaltrexone is an antagonist of opioid binding at the mu-opioid receptor. It does not cross the blood brain barrier; it is a peripherally-acting mu-opioid receptor antagonist in tissues, including the gastrointestinal tract, thereby decreasing the constipating effects of opioids without impacting with the centrally opioid-mediated effects of opioid analgesia.

Opioid receptors are widely distributed in the central and peripheral nervous system, intestines, and other tissues. There are three types of receptors involved in mediating the effects of opioids. These include delta, kappa, and mu receptors. They belong to the family of G-protein coupled receptors that regulate adenylate cyclase. Stimulation of the receptor results in inhibition of adenylate cyclase with a reduction of neuron excitability and neurotransmitter release. The end result is inhibition of the affected neuron.

Opioids & Constipation:

- Opioid medications are increasingly used not only for the management of acute pain but also for the long term management of cancer related and non-cancer related chronic pain syndromes
- With increased use of opioids for pain there is also an increase in adverse effects from their use which includes OIC and opioid bowel dysfunction
- Constipation is a syndrome that may be defined by symptoms of difficult or infrequent passage of stool, hardness of stool, or a feeling of incomplete evacuation that may occur either alone or due to another medical disorder
 - The definition of constipation will differ from individual to individual, culture to culture, and even region to region
 - Patients may define constipation as straining during defecation or change in stool consistency or frequency
- Bristol Stool Form Scale – seven types of stool are:
 - Type 1: Separate hard lumps, like nuts (hard to pass); also known as *goat feces*
 - Type 2: Sausage-shaped, but lumpy
 - Type 3: Like a sausage but with cracks on its surface
 - Type 4: Like a sausage or snake, smooth and soft
 - Type 5: Soft blobs with clear cut edges (passed easily)
 - Type 6: Fluffy pieces with ragged edges, a mushy stool
 - Type 7: Watery, no solid pieces, entirely liquid

RELISTOR® (methylnaltrexone bromide) oral tablet and subcutaneous injection (cont.)

- Types 1 and 2 indicate constipation, with types 3 and 4 indicating the ideal stools (especially the latter), as they are easy to defecate while not containing excess liquid, and types 5, 6 and 7 specify diarrheal stools
- Functional constipation may be defined by the Rome IV criteria as the presence of at least **two** of the following:
 - Straining during at least 25% of bowel movements
 - Passage of lumpy or hard stools at least 25% of bowel movements
 - Sensation of incomplete evacuation at least 25% of bowel movements
 - Anorectal obstruction or blockage at least 25% of bowel movements
 - The need to use manual maneuvers to facilitate defecation at least 25% of bowel movements
 - Passing fewer than three stools per week
- OIC is a result of use of opioid medications with ensuing loss of gastrointestinal tone, contractility, and mobility
 - OIC is defined as:
 - New or worsening symptoms of constipation when initiating, changing, or increasing opioid therapy
 - Must include two or more of the symptoms defining functional constipation (see above) with the same frequency cutoff (25%)
- The cause of OIC is multifactorial and includes:
 - Inhibition of gastric emptying
 - Reduction of mucosal secretions
 - Reduced bowel tone and contractility
 - Decreased peristalsis with delayed transit
 - Increased fluid and electrolyte absorption from increased contact time
- Tolerance to opioid induced gastrointestinal adverse effects does not occur
- Chronic constipation can result in:
 - Hemorrhoid formation
 - Rectal pain and burning
 - Bowel obstruction, and bowel rupture
 - Upper gut dysfunctions, including gastroesophageal reflux disease, nausea, and abdominal distention

Definitions:

Laxative types:

Bulk forming – calcium polycarbophil, cellulose, fiber, malt soup, methylcellulose, psyllium
Osmotic – glycerin, lactulose, polyethylene glycol, sodium phosphate, sorbitol
Lubricating/emollient – mineral oil
Saline – magnesium citrate, magnesium hydroxide, magnesium oxide, magnesium sulfate
Softener – dioctyl calcium sulfosuccinate, dioctyl sodium sulfosuccinate



PHARMACY COVERAGE GUIDELINES
SECTION: DRUGS

ORIGINAL EFFECTIVE DATE: 4/1/19
LAST REVIEW DATE: 2/21/19
LAST CRITERIA REVISION DATE:
ARCHIVE DATE:

RELISTOR® (methylnaltrexone bromide) oral tablet and subcutaneous injection (cont.)

Stimulant/irritant – bisacodyl, sennosides
Other – castor oil, ceo-two

Prokinetic agent:
Metoclopramide

Resources:

Relistor (methylnaltrexone) product information accessed 12-26-18 at DailyMed:
<https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c488fb7c-0a5b-487c-b452-996809d1cb99>

UpToDate: Prevention and management of side effects in patients receiving opioids for chronic pain. Current through Sep 2017. https://www.uptodate-com.mwu.idm.oclc.org/contents/prevention-and-management-of-side-effects-in-patients-receiving-opioids-for-chronic-pain?source=search_result&search=opioid%20induced%20constipation&selectedTitle=1~40



An Independent Licensee of the Blue Cross and Blue Shield Association

Fax completed prior authorization request form to 602-864-3126 or email to pharmacyprecert@azblue.com. Call 866-325-1794 to check the status of a request. All requested data must be provided. Incomplete forms or forms without the chart notes will be returned. Pharmacy Coverage Guidelines are available at www.azblue.com/pharmacy.

Pharmacy Prior Authorization Request Form

Do not copy for future use. Forms are updated frequently.

REQUIRED: Office notes, labs, and medical testing relevant to the request that show medical justification are required.

Member Information			
Member Name (first & last):	Date of Birth:	Gender:	BCBSAZ ID#:
Address:	City:	State:	Zip Code:

Prescribing Provider Information			
Provider Name (first & last):	Specialty:	NPI#:	DEA#:
Office Address:	City:	State:	Zip Code:
Office Contact:	Office Phone:	Office Fax:	

Dispensing Pharmacy Information		
Pharmacy Name:	Pharmacy Phone:	Pharmacy Fax:

Requested Medication Information			
Medication Name:	Strength:	Dosage Form:	
Directions for Use:	Quantity:	Refills:	Duration of Therapy/Use:

Check if requesting **brand** only Check if requesting **generic**

Check if requesting continuation of therapy (prior authorization approved by BCBSAZ expired)

Turn-Around Time For Review	
<input type="checkbox"/> Standard <input type="checkbox"/> Urgent. Sign here: _____	<input type="checkbox"/> Exigent (requires prescriber to include a written statement)

Clinical Information

1. **What is the diagnosis? Please specify below.**
 ICD-10 Code: _____ Diagnosis Description: _____

2. Yes No **Was this medication started on a recent hospital discharge or emergency room visit?**

3. Yes No **There is absence of ALL contraindications.**

4. **What medication(s) has the individual tried and failed for this diagnosis? Please specify below.**
 Important note: Samples provided by the provider are not accepted as continuation of therapy or as an adequate trial and failure.

Medication Name, Strength, Frequency	Dates started and stopped or Approximate Duration	Describe response, reason for failure, or allergy

5. **Are there any supporting labs or test results? Please specify below.**

Date	Test	Value

Pharmacy Prior Authorization Request Form

6. Is there any additional information the prescribing provider feels is important to this review? Please specify below.
For example, explain the negative impact on medical condition, safety issue, reason formulary agent is not suitable to a specific medical condition, expected adverse clinical outcome from use of formulary agent, or reason different dosage form or dose is needed.

Signature affirms that information given on this form is true and accurate and reflects office notes

Prescribing Provider's Signature:	Date:
-----------------------------------	-------

Please note: Some medications may require completion of a drug-specific request form.

Incomplete forms or forms without the chart notes will be returned.

Office notes, labs, and medical testing relevant to the request that show medical justification are required.